The RET gene and its associated diseases
Hofstra, Robert Martinus Wouter

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
1995

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Summary / Samenvatting
Summary

This thesis starts with a brief description of protein kinases, a large family of proteins involved in cell proliferation and differentiation and also in a number of cancer types and hereditary diseases (chapter 1), and subsequently discusses in greater detail the receptor protein kinase RET (chapter 2) and its involvement in several diseases (chapter 3). Furthermore, our own data on the RET gene and its role in diseases as well as results obtained in collaborative efforts with other groups are presented in the appendices 2-7.

The RET protein is involved in the normal development and the neoplastic growth of neural crest lineages. The ligand of the receptor is as yet unidentified. During embryogenesis, RET expression is high in neuroectodermal tissues, suggesting a function of RET in the proliferation, the migration and the differentiation of these cell types. In adult tissues the gene is hardly expressed. Expression is high in several tumor types derived from neural crest cells (chapter 2).

Transfection studies with DNA from different tumors revealed focal proliferation due to the presence of different DNA sequences that, however, shared a common part called RET. The original RET gene turned out to be rearranged in such a way that the sequences coding for the extracellular part of its protein product were replaced by sequences from elsewhere, resulting in a rearranged protein with a steady tyrosine kinase activity. The same rearrangement occurs in papillary thyroid carcinoma (PTC) (chapter 3).

After the genes involved in multiple endocrine neoplasia types 2A (MEN 2A) and 2B (MEN 2B) had been mapped to the centromeric region of chromosome 10 by linkage analysis, mutations of RET, a gene present in this very region, appeared responsible for the development of MEN 2A. The establishment of the intron-exon junctions of the RET gene and the determination of the flanking intronic sequences in a collaborative effort with the group of professor Romeo (Genua, Italy), made it possible to design primers and to develop PCR conditions for SSCP analysis (Appendices 2 and 3). Using this mutation detection system (Appendix 3) we found that a single RET mutation is uniquely associated with MEN 2B (Chapter 3 and Appendix 5).

In some families, MEN 2A is also found associated with cutaneous lichen amyloidosis (CLA), a rare skin disorder. We screened two of these families for RET mutations to determine whether specific mutations are involved in these families. A Cys634→Arg mutation was found. Though the same codon was affected in an earlier described family, the mutation in that family was different. This makes it hard to suggest a correlation between MEN 2A associated with CLA and a specific RET mutation. Because of the association of CLA with MEN 2A, RET might also be involved in hereditary "CLA only". We, therefore, screened RET in three families with hereditary CLA, but did not find any mutation. We concluded that the CLA lesions found in MEN 2A patients and those found in inherited CLA without MEN 2A must be caused by different genes. (chapter 3 and appendix 7).

An estimated 25% of medullary thyroid carcinomas (MTC) appear in the context of inherited disease (MEN 2 syndromes and familial MTC). For pheochromocytoma, the percentage of cases being part of an inherited neoplastic syndrome (MEN 2A, von Hippel Lindau,
neurofibromatosis I) is similar to that in MTC. The large majority of MTC and pheochromocytoma, however, consists of sporadic cases. We analyzed RET in sporadic MTC and RET and the von Hippel Lindau gene (VHL) in pheochromocytoma for the presence of mutations. In sporadic MTC and in sporadic pheochromocytoma RET mutations appeared to account for only a proportion of cases. The same could be concluded for the VHL gene in pheochromocytoma (chapter 3 and appendix 5).

Besides the gene for the neoplastic syndromes MEN 2A and MEN 2B, the gene for Hirschsprung disease could also be mapped by linkage analysis to the same small region of chromosome 10. Using the RET mutation detection system described in appendix 3, the Romeo group was one of two research groups who demonstrated that HSCR was also associated with RET mutations. The mutations appeared to be scattered all over the gene (chapter 3).

Publications in the recent literature on RET explain how these different diseases can be caused by one single gene. These are discussed in chapter 3. Mutations causing MEN 2A and MEN 2B activate the protein product, whereas mutations for HSCR result in a loss of function of the translated protein (chapter 3).

Based on the involvement of RET in the development of neural crest-derived tissues and on the association of RET mutations with neurocristopathies such as the MEN 2 syndromes and HSCR, a search for RET mutations in other neurocristopathies seems justified. Neuroblastoma occasionally occurs in diseases associated with abnormal neurocrest differentiation, e.g. Hirschsprung disease. Furthermore, neuroblastomas express RET. We therefore scanned the entire RET gene in 16 neuroblastoma cell lines and in a neuroblastoma patient belonging to a family in which different neurocristopathies occurred, including Hirschsprung disease and ganglioneuroma. We did not find any RET mutation. Therefore, expression of RET in neuroblastoma might just reflect the differentiation status of the tumor cells, rather than indicating an involvement in the tumorigenesis of neuroblastoma (chapter 3 and appendix 7).

We may conclude that RET, as a gene in which different mutations lead to different diseases, is a good example of allelic heterogeneity. On the other hand, in some diseases RET plays a role in only a proportion of the cases and other, yet unidentified, genes account for the remaining cases. Therefore, RET is also a good example of non-allelic heterogeneity.